HBsAg弱阳性及HBsAg和HBsAb同时阳性的结果分析

目的对ELISA法检测乙肝五项结果中的HBsAg弱阳性结果及乙型肝炎HBsAg和HBsAb同时阳性的结果进行分析。方法从35 280例乙肝五项ELISA法检测结果中筛出HBsAg弱阳性115例,HBsAg和HBsAb双阳性结果95例,对筛出的210例标本再进行电化学发光(ECLIA)定量检测。结果 115例HBsAg弱阳性结果用ECLIA检测,结果一致为90例。符合率为78.3%。HBsAg和HBsAb双阳性结果95例用ECLIA检测,结果一致为11例。符合率为11.6%。结论 ELISA法检测乙肝五项对HBsAg弱阳性及HBsAg和HBsAb双阳性结果要慎重。HBsAg弱阳性结果中以HBsAg、HBeAb、HBcAb阳性和HBsAg、HBcAb阳性标本占大多数。HBsAg和HBsAb同时阳性的结果可靠性差,要慎重发出报告。     

量子点电化学发光的研究现状

本文介绍了近年来基于量子点电化学发光的最新研究进展,叙述了以量子点为基础的电化学发光在免疫检测和其它检测方面的应用现状,最后探讨了量子点电化学发光传感器在生化检测中的应用前景和面临的挑战.     

血清相关肿瘤标记物联合检测对消化道恶性肿瘤的临床价值研究

目的：探讨血清甲胎蛋白（AFP）、癌胚抗原（CEA）、糖类抗原19‐9（CA19‐9）、糖类抗原72‐4（CA72‐4）联合检测在消化道恶性肿瘤诊断,病情监测及疗效观察中的价值。方法该院体检健康者60例纳入对照组,该院消化道恶性肿瘤患者186例纳入消化道恶性肿瘤组,其中肝癌亚组56例,胰腺癌亚组32例,胃癌亚组63例,结肠癌亚组35例。采用电化学发光免疫技术检测所有被试血清 AFP 、CEA 、CA19‐9、CA72‐4水平。结果消化道恶性肿瘤患者血清 AFP 、CEA 、CA19‐9、CA72‐4的水平明显高于对照组,差异有统计学意义（P＜0．05）,其中血清 AFP 水平在肝癌亚组,CEA 水平在结直肠癌亚组,CA19‐9水平在胰腺癌亚组,CA72‐4水平在胃癌亚组中明显高于其他各组（P＜0．05）。肝癌、胰腺癌亚组中,联合检测 AFP 、CEA 、CA19‐9的阳性率明显高于单项检测（P＜0．05）;胃癌、结肠癌亚组中,联合检测 CEA 、CA19‐9、CA72‐4的阳性率明显高于单项检测（P＜0．05）。结论血清 AFP 、CEA 、CA19‐9、CA72‐4联合检测有助于提高消化道肿瘤诊断的灵敏度。对肝癌、胰腺癌检测以 AFP 、CEA 、CA19‐9联合检测最佳,胃癌、结肠癌以 CEA 、CA19‐9、CA72‐4联合检测最佳。     

肿瘤标记物CA125检测对肺癌的诊断价值

目的:探讨肿瘤标记物CA125水平变化及其在肺癌诊断中的价值。方法:对已确诊的54例肺癌患者及29例良性肺部疾病患者的CA125浓度用电化学发光法进行检测,并对结果进行统计学分析。结果:54例肺癌患者的CA125阳性率为55.17%,29例良性肺部疾病患者的CA125阳性率10.71%。可以得出:肺癌患者与肺良性病患者之间有显著性差异(P<0.005),CA125肺癌诊断特异性为87.5%,敏感性为55.17%。结论:检测血清中CA125水平的变化有助于肺部良恶性疾病的鉴别诊断,并可作为疗效及预后判断的指标。     

CYFRA21-1、CA153联合检测对乳腺癌的诊断意义

目的探讨血清CYFRA21-1、CA153联合检测对乳腺癌的诊断意义.方法采用电化学发光法检测CYFRA21-1和CA153,将乳腺癌患者血清的测定结果与正常女性对照组及乳腺良性肿瘤组进行比较.结果乳腺癌患者的血清CYFRA21-1、CA153水平及阳性率均明显高于正常女性对照组及乳腺良性肿瘤对照组（P＜0.05）;联合检测的敏感度和诊断准确性均比单项检测高.结论联合检测血清中CYFRA21-1和CA153对乳腺癌的诊断具有重要的临床意义.     

Direct detection of bacteria in cellular blood products using bacterial ribosomal RNA-directed probes coupled to electrochemiluminescence

Various techniques for detecting bacteria in blood products exist; however, none has been widely accepted. Our method permits direct bacterial detection in both platelet concentrates (PC) and packed red blood cells (RBC). This novel procedure targets bacterial ribosomal RNA (rRNA) but does not utilize culture or nucleic acid amplification. The assay comprises five steps: (1) release of bacterial rRNA by cell lysis with a combination of detergents and high heat; (2) hybridization of bacterial rRNA using a biotin- and a ruthenium (ORIGEN)-labelled oligonucleotide probe pair; (3) capture of labelled rRNA with streptavidin-coated magnetic beads; (4) concentration of labelled rRNA/bead complexes out of solution and onto an electrode surface with a magnet; (5) detection of ruthenium-labelled bacterial rRNA by application of voltage and consequent generation of the electrochemiluminescent (ECL) signal. Results using PC and RBC samples, spiked with clinically relevant gram-negative and -positive bacterial species, consistently demonstrated a linear relationship between ECL signal (equates to rRNA level) and colony forming units (CFU) mL(-1). Signals were generated in the range of 1400-80000 and 3500-500000 ECL units for unwashed and washed samples, respectively. This is equivalent to 10(5)-10(8)CFU mL(-1). These data demonstrate that therapeutic blood products significantly contaminated with bacteria may be identified prior to issue.     

F/T比值在乳腺癌诊断和预后评估中的应用

目的探讨血清游离前列腺特异性抗原（FPSA）与总前列腺特异性抗原（TPSA）比值（F/T）在女性乳腺疾病中的临床应用价值。方法用电化学发光法（ECL）检测47例乳腺癌患者、34例乳腺良性增生患者和30例正常女性的血清FPSA、TPSA,并计算F/T比值,评价其在女性乳腺疾病的诊断和预后评估价值。结果以F/T比值为0.15为判断上限时,其阳性诊断率为46.8%,明显高于TPSA和FPSA单测时的阳性诊断率。结论血清F/T比值在女性乳腺疾病诊断和预后评估方面具有重要临床应用价值。     

Capillary electrophoresis with electrochemiluminescence detection for simultaneous determination of proline and fleroxacin in human urine

The content of free proline (Pro) in body fluids is a biological parameter for patients with renal insufficiency and chronic uraemia. Fleroxacin (FLX) must be used cautiously because of adverse reactions. Its dosage must be adjusted according to the degree of renal insufficiency. In a clinical setting the simultaneous determination of Pro and FLX in body fluids is necessary for the rational utilization of FLX. A capillary electrophoresis (CE) method based on electrochemiluminescence (ECL) detection with Ru(bpy)₃²⁺ was developed for the simultaneous determination of Pro and FLX in human urine. Parameters related to separation and detection were investigated and optimized. The most favourable resolution and high sensitivity were obtained using a 15 mM phosphate buffer at pH 9.6 with the detection potential at 1.15 V. Under optimized conditions, the standard curves were linear in the range of 0.1–80 µg/mL for Pro and 0.1–100 µg/mL for FLX. Detection limits(3σ) of 0.3 ng/mL for FLX and 0.02 µg/mL for Pro were obtained. Relative standard derivations (RSDs) of the ECL intensity and the migration time were 3.2% and 0.9% for 4 µg/mL Pro and 3.7% and 1.2% for 4 µg/mL FLX, respectively. The recoveries were in the range of 94.8–99.6% for Pro with RSDs of 2.8%–3.6% and 94.7–97.8% for FLX with RSDs of 2.9%–3.7%. The proposed method was successfully applied to determine the amounts of Pro and FLX in human urine. Copyright © 2009 John Wiley & Sons, Ltd.     

AFP、CEA检测对良恶性腹腔积液的诊断价值

目的:探讨腹腔积液患者甲胎蛋白(alpha-fetoprotein,AFP)、癌胚抗原(carcinoembryonic antigen,CEA)表达水平对良恶性腹腔积液的诊断价值。方法:回顾性分析本院97例腹腔积液患者的临床资料,按照腹腔积液性质分为良性组42例和恶性组55例,应用罗氏Cobas E601全自动电化学发光免疫分析仪检测并比较两组患者血清和腹腔积液中AFP、CEA的测定结果。结果:恶性腹腔积液组血清和腹腔积液表达均显著高于良性腹腔积液组的表达(P<0.05);恶性腹腔积液组AFP和CEA的腹腔积液/血清比值显著高于良性组(P<0.05);腹腔积液AFP和CEA的表达同血清中的表达比较具有显著性差异(P<0.05)。单项肿瘤标志物检测腹腔积液AFP检测的准确度最高,两项指标联合检测腹腔积液检测的准确度高于血清检测的准确度(P<0.05)。结论:检测腹腔积液患者AFP、CEA表达水平有助于积液性质的良恶性鉴别;腹腔积液AFP、CEA的检测对恶性腹腔积液的诊断较血清学检测更有价值;肿瘤标志物联合检测能提高恶性腹腔积液诊断的准确度。